Evidence map›Paper›PMID 34843523›Full record

ArticlePloS one2021

Transcriptomic analysis of human skin wound healing and rejuvenation following ablative fractional laser treatment.

Joseph D Sherrill, Deborah Finlay, Robert L Binder, Michael K Robinson, Xingtao Wei, Jay P Tiesman, Michael J Flagler, Wenzhu Zhao, Catherine Miller, Jean M Loftus and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Safety and Tolerability of Fractional COJournal of cosmetic dermatology · 2026
    Article
  8. Article
  9. An Overview of the Mechanisms of Fractional COLasers in medical science · 2026
    Review
  10. Therapeutic effect of low-level 10,600 nm COLasers in medical science · 2025
    Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Joseph D SherrillThe Procter & Gamble Company, Cincinnati, OH, United States of America.
Deborah FinlayThe Procter & Gamble Company, Cincinnati, OH, United States of America.ORCID 0000-0001-7612-1069
Robert L BinderThe Procter & Gamble Company, Cincinnati, OH, United States of America.ORCID 0000-0002-2678-4881
Michael K RobinsonThe Procter & Gamble Company, Cincinnati, OH, United States of America.
Xingtao WeiThe Procter & Gamble Company, Cincinnati, OH, United States of America.
Jay P TiesmanThe Procter & Gamble Company, Cincinnati, OH, United States of America.ORCID 0000-0002-0632-0369
Michael J FlaglerThe Procter & Gamble Company, Cincinnati, OH, United States of America.
Wenzhu ZhaoThe Procter & Gamble Company, Cincinnati, OH, United States of America.
Catherine MillerLoftus Plastic Surgery Center, Fort Wright, KY, United States of America.
Jean M LoftusLoftus Plastic Surgery Center, Fort Wright, KY, United States of America.
Alexa B KimballBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America.
Charles C BascomThe Procter & Gamble Company, Cincinnati, OH, United States of America.ORCID 0000-0001-9532-7425
Robert J IsfortThe Procter & Gamble Company, Cincinnati, OH, United States of America.ORCID 0000-0002-0202-1361
Procter & Gamble (United States) · USBeth Israel Deaconess Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ablative fractional laser treatment is considered the gold standard for skin rejuvenation. In order to understand how fractional laser works to rejuvenate skin, we performed microarray profiling on skin biopsies to identify temporal and dose-response changes in gene expression following fractional laser treatment. The backs of 14 women were treated with ablative fractional laser (Fraxel®) and 4 mm punch biopsies were collected from an untreated site and at the treated sites 1, 3, 7, 14, 21 and 28 days after the single treatment. In addition, in order to understand the effect that multiple fractional laser treatments have on skin rejuvenation, several sites were treated sequentially with either 1, 2, 3, or 4 treatments (with 28 days between treatments) followed by the collection of 4 mm punch biopsies. RNA was extracted from the biopsies, analyzed using Affymetrix U219 chips and gene expression was compared between untreated and treated sites. We observed dramatic changes in gene expression as early as 1 day after fractional laser treatment with changes remaining elevated even after 1 month. Analysis of individual genes demonstrated significant and time related changes in inflammatory, epidermal, and dermal genes, with dermal genes linked to extracellular matrix formation changing at later time points following fractional laser treatment. When comparing the age-related changes in skin gene expression to those induced by fractional laser, it was observed that fractional laser treatment reverses many of the changes in the aging gene expression. Finally, multiple fractional laser treatments, which cover different regions of a treatment area, resulted in a sustained or increased dermal remodeling response, with many genes either differentially regulated or continuously upregulated, supporting previous observations that maximal skin rejuvenation requires multiple fractional laser treatments. In conclusion, fractional laser treatment of human skin activates a number of biological processes involved in wound healing and tissue regeneration.

Indexed as

AdultAgingBiopsyEpidermal CellsEpidermisFemaleGene ExpressionGene Expression ProfilingHumansLaser TherapyMiddle AgedRejuvenationRNASkinTranscriptomeWound HealingRNA

Identifiers

PMID34843523
PMCPMC8629261
OpenAlexW3217695042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.